GlassScriptPhysician profile
Nancy Y Olson
NPI 1265543466
$15,415.09
in general payments reported to CMS, 2019-2025
44 companies · $3,419 in 2025
The $3,419 reported for 2025 was more than what 85% of Pediatric Rheumatology providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $718 · 2021: $1,346 · 2022: $2,355 · 2023: $3,237 · 2024: $3,306 · 2025: $3,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,787 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,786.68 |
| Education | $175.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,606.86 | 2019-2025 | |
| Amgen INC. | $1,435.90 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Astrazeneca Pharmaceuticals LP | $1,312.19 | 2019-2025 | Saphnelo, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $922.83 | 2020-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $821.38 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $789.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $723.69 | 2021-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $672.47 | 2020-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $575.88 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Csl Behring | $573.97 | 2019-2025 | Haegarda, Hizentra, Andembry |
| E.R. Squibb & Sons, L.L.C. | $559.72 | 2019-2025 | Orencia |
| Genentech USA, INC. | $552.67 | 2019-2025 | Xolair, Actemra |
| Lilly USA, LLC | $496.25 | 2019-2025 | Taltz, Zepbound |
| Hospira, INC. | $447.42 | 2022-2025 | |
| Ucb, INC. | $388.54 | 2019-2025 | Cimzia, Bimzelx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $345.23 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $288.33 | 2022-2024 | Purified Cortrophin Gel |
| Pfizer INC. | $179.98 | 2021-2025 | |
| Pharming Healthcare, INC. | $173.83 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $165.35 | 2023-2025 | Orladeyo |
| Horizon Therapeutics Plc | $132.87 | 2019-2022 | |
| Sandoz INC. | $126.61 | 2023-2025 | Hyrimoz |
| Grifols USA, LLC | $120.24 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Shire North American Group INC | $108.59 | 2019 | |
| Fresenius Kabi USA, LLC | $103.25 | 2023-2025 | Idacio |
| Sobi, INC | $88.69 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $85.69 | 2019-2025 | Strensiq |
| Gilead Sciences, INC. | $68.37 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.52 | 2020-2024 | Cyltezo |
| Xeris Pharmaceuticals, INC. | $52.65 | 2024 | Keveyis |
| Tersera Therapeutics LLC | $47.48 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $45.38 | 2021-2023 | Arcalyst |
| Blueprint Medicines Corporation | $43.54 | 2023-2024 | Ayvakit |
| Organon LLC | $43.45 | 2023-2025 | Renflexis, Hadlima |
| Teva Pharmaceuticals USA, INC. | $40.29 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $39.24 | 2022-2023 | Opsumit, Uptravi |
| Octapharma USA, INC. | $30.95 | 2020-2023 | Cutaquig |
| Celltrion USA INC. | $29.44 | 2023 | Yuflyma |
| Azurity Pharmaceuticals, INC. | $25.44 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $22.33 | 2025 | Dawnzera |
| Invivyd INC | $18.90 | 2025 | Pemgarda |
| Celgene Corporation | $18.35 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.25 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $17.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.